Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Non-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), we hypothesized that biomarkers of immune dysregulationpreviously defined in patients with congenital CTLA4 deficiency, including elevated soluble interleukin-2 receptor alpha (sIL-2R) and flow cytometric cell-based markers of B and T cell dysregulation in peripheral blood may aid the diagnosis of ICI-nephritis. Methods: A retrospective cohort of patients diagnosed with ICI-nephritis was compared with three prospectively enrolled control cohorts: ICI-treated controls without immune-related adverse events, patients not on ICIs with hemodynamic acute kidney injury (hemodynamic AKI), and patients not on ICIs with biopsy proven acute interstitial nephritis from other causes (non-ICI-nephritis). sIL-2R level and flow cytometric parameters were compared between groups using Wilcoxon rank sum test or Kruskal-Wallis test. Receiver operating characteristic curves were generated to define the accuracy of sIL-2R and flow cytometric biomarkers in diagnosing ICI-nephritis. The downstream impact of T cell activation in the affected kidney was investigated using archived biopsy samples to evaluate the gene expression of IL2RA, IL-2 signaling, and T cell receptor signaling in patients with ICI-nephritis compared with other causes of drug-induced nephritis, acute tubular injury, and histologically normal controls. Results: sIL-2R level in peripheral blood was significantly higher in patients with ICI-nephritis (N=24) (median 2.5-fold upper limit of normal (ULN), IQR 1.9–3.3), compared with ICI-treated controls (N=10) (median 0.8-fold ULN, IQR 0.5–0.9, p<0.001) and hemodynamic AKI controls (N=6) (median 0.9-fold-ULN, IQR 0.7–1.1, p=0.008). A sIL-2R cut-off point of 1.75-fold ULN was highly diagnostic of ICI-nephritis (area under the curve >96%) when compared with either ICI-treated or hemodynamic AKI controls. By peripheral blood flow cytometry analysis, lower absolute CD8+T cells, CD45RA+CD8+ T cells, memory CD27+B cells, and expansion of plasmablasts were prominent features of ICI-nephritis compared with ICI-treated controls. Gene expressions for IL2RA , IL-2 signaling, and T cell receptor signaling in the kidney tissue with ICI-nephritis were significantly higher compared with controls. Conclusion: Elevated sIL-2R level and flow cytometric markers of both B and T cell dysregulation may aid the diagnosis of ICI-nephritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 1×
“12 Robust T cell infiltrates are a classic pathologic feature of irAEs involving different organ systems (34, 35) as well as non-ICI drug-induced acute interstitial nephritis (36).”
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.001 · Cited by 484 · cited 1×
“12 Robust T cell infiltrates are a classic pathologic feature of irAEs involving different organ systems (34, 35) as well as non-ICI drug-induced acute interstitial nephritis (36).”
Self-citationAbatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901677 · Cited by 443
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070676 · Cited by 407
Self-citationLim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381
Haslam, A., Gill, J., & Prasad, V. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.0423 · Cited by 283 · cited 2×
“The latest estimates suggest that approximately 38% of all patients with cancer qualify for ICI treatment (2).”
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina, D. G., Wilson, F. P., Pober, J. S., Perazella, M. A., Singh, N., Luciano, R. L., Obeid, W., Lin, H., Kuperman, M., Moeckel, G. W., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127456 · Cited by 154
Involvement of Drug-Specific T Cells in Acute Drug-Induced Interstitial Nephritis
Spanou, Z., Keller, M., Britschgi, M., Yawalkar, N., Fehr, T., Neuweiler, J., Gugger, M., Mohaupt, M., & Pichler, W. J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050418 · Cited by 151 · cited 1×
“12 Robust T cell infiltrates are a classic pathologic feature of irAEs involving different organ systems (34, 35) as well as non-ICI drug-induced acute interstitial nephritis (36).”
Clinical Approach to Diagnosing Acute and Chronic Tubulointerstitial Disease
Perazella, M. A. (2017) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.08.003 · Cited by 79 · cited 1×
“2 13–15 Yet, important treatment decisions that can affect both kidney function and cancer outcomes depend on accurate diagnosis of ICI-nephritis.”
Cited by
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67
Self-citationMiao, J., & Herrmann, S. M. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad109 · Cited by 31
“Furthermore, systemic soluble interleukin-2 receptor (sIL-2R) has been found to be elevated in patients with ICI-AIN compared to ICI-treated controls and hemodynamic AKI controls (median 2.5-fold upper limit of normal vs 0.8-and 0.9-fold, P 0.001 and P = 0.008, respectively) [83].”
BackgroundResultInfluentialSelf-citationSeethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15
Self-citation
Metadata
- Authors
- Sise, M. E., Wang, Q., Seethapathy, H., Moreno, D., Harden, D., Smith, R. N., Rosales, I. A., Colvin, R. B., Chute, S., Cornell, L. D., Herrmann, S. M., Fadden, R., Sullivan, R. J., Yang, N. J., Barmettler, S., Wells, S., Gupta, S., Villani, A.-C., Reynolds, K. L., & Farmer, J.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2023-01
- Volume
- 11
- Issue
- 1
- Pages
- e006222
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W4317500246
- Cited by
- 48
- References
- 11
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. https://app.cochat.ai/papers/10.1136/jitc-2022-006222
- The paper
- Sise, M. E., Wang, Q., Seethapathy, H., Moreno, D., Harden, D., Smith, R. N., Rosales, I. A., Colvin, R. B., Chute, S., Cornell, L. D., Herrmann, S. M., Fadden, R., Sullivan, R. J., Yang, N. J., Barmettler, S., Wells, S., Gupta, S., Villani, A.-C., Reynolds, K. L., & Farmer, J. (2023). Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.